Steba Biotech

aka STEBA Biotech S.A.

Steba Biotech developed padeliporfin, a light-activated drug injected into the bloodstream and switched on by laser fibres in the prostate to destroy low-risk prostate cancer, approved in Europe as Tookad.

Steba Biotech developed vascular-targeted photodynamic therapy with padeliporfin (WST11, Tookad), a bacteriochlorophyll derivative created at the Weizmann Institute of Science. The drug is infused intravenously and activated by near-infrared light delivered through fibres placed in the prostate, causing rapid vessel occlusion and tumour necrosis. The European Commission approved Tookad in 2017 for unilateral low-risk prostate cancer after a randomised trial against active surveillance; it is also being studied in upper tract urothelial cancer.

Headquarters

Luxembourg, LU

Scorecard

All companies

#257of 1181 companies, score 15

approved products +6
modalities +2
regions +1
registry trials +6

1 approved, 0 in phase 3, 0 earlier, 0 targets, 10 registry studies. Formula on the scorecards page.

Type

pharma

Products

1top

ApprovedIntravenous photosensitiser for vascular-targeted photodynamic therapy

Padeliporfin · Tookad

Tookad is a light-activated drug for men with low-risk prostate cancer in one side of the prostate. It is infused and then switched on with laser fibres placed in the gland, destroying the cancer-bearing tissue as an alternative to watchful waiting.

Connected